Date Filed | Type | Description |
09/29/2023 |
6-K
| Quarterly results |
07/07/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/04/2023 |
6-K
| Quarterly results |
04/28/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
04/28/2023 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
04/18/2023 |
6-K
| Quarterly results |
03/28/2023 |
6-K
| Quarterly results |
02/09/2023 |
SC 13G/A
| FMR LLC reports a 8.8% stake in ADAGENE INC |
02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
01/09/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
12/16/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
11/21/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
09/12/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
08/31/2022 |
6-K
| Quarterly results |
06/29/2022 |
6-K
| Quarterly results |
05/27/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
05/26/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/20/2022 |
F-3/A
| Form F-3/A - Registration statement by foreign private issuers: [Amend] |
05/13/2022 |
F-3/A
| Form F-3/A - Registration statement by foreign private issuers: [Amend] |
05/02/2022 |
DEL AM
| Form DEL AM - Delaying amendment: |
04/29/2022 |
SC 13D
| Luo Peter reports a 20.8% stake in Adagene, Inc. |
04/26/2022 |
F-3
| Form F-3 - Registration statement by foreign private issuers: |
04/26/2022 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
04/08/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
03/31/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
03/16/2022 |
6-K
| Quarterly results |
03/09/2022 |
6-K
| Quarterly results |
03/02/2022 |
6-K
| Quarterly results |
02/11/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
02/09/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/09/2022 |
SC 13G
| Luo Peter reports a 20.2% stake in Adagene Inc. |
01/27/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
|
"FORM 6-K",
"Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116 SAN DIEGO and SUZHOU, China, January 27, 2022 - Adagene Inc. , a company transforming the discovery and development of novel antibody-based therapies, today announced the first patient has been dosed in a combination cohort of its anti-CD137 agonist, ADG106, with its anti-CTLA-4 monoclonal antibody , ADG116, in patients with advanced/metastatic solid tumors. The dose escalation cohort will evaluate the safety and tolerability of this novel, proprietary combination in patients with advanced/metastatic solid tumors. “Existing cancer therapies that target CD137 and CTLA-4 are associated with safety concerns, creating a significant unmet need and ..." |
|
01/26/2022 |
SC 13G
| WuXi PharmaTech Healthcare Fund I L.P. reports a 9.7% stake in Adagene Inc. |
01/26/2022 |
SC 13G
| JSR Ltd reports a 9.8% stake in Adagene Inc. |
|